Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>
Actos Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>
研究概览
详细说明
This survey was designed to evaluate the effects on glycemic control and to evaluate the safety of long-term use of pioglitazone tablets (Actos Tablets) in type 2 diabetic patients with inadequate glycemic control and a prior history of cerebral infarction.
For adults, 15-30 mg of pioglitazone is usually administered orally once daily before or after breakfast. The dose should be adjusted depending on sex, age, and symptoms; however, the maximum daily dose should not exceed 45 mg.
研究类型
注册 (实际的)
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
Type 2 diabetic patients with a prior history of cerebral infarction who meet all the following conditions, [1] to [3], at the time of enrollment in the survey:
- First onset of cerebral infarction was at least 24 weeks prior to enrollment
- HbA1c values ≥ 6.5% within 12 weeks prior to the start of treatment with Pioglitazone Tablets
- No prior history of treatment with Pioglitazone Tablets since the first onset of cerebral infarction
Exclusion Criteria:
Patients who meet any of the following conditions, [1] to [5], shall be excluded from the survey:
- Contraindication for Actos Tablets
- Prior history of recurrence of cerebral infarction
- Prior history of cerebral hemorrhage or subarachnoid hemorrhage
- Complications or prior history of myocardial infarction, angina pectoris, cardiomyopathy, hypertensive heart disease, atrial fibrillation, atrial flutter, or valvular disease
- Reduced cardiac function (defined as an ejection fraction [EF] ≤ 40%)
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
Pioglitazone
Pioglitazone 15-30 mg, tablet, orally, once daily for up to 48 weeks before or after breakfast (the dose can be adjusted; however, the maximum daily dose should not exceed 45 mg).
|
吡格列酮片
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Percentage of Participants Achieving Good Glycemic Control (Reduction in Fasting Blood Glucose Level < 130 mg/dL)
大体时间:48 Week
|
The reported data were percentage of participants who achieved good glycemic control at 48 Week.
Good glycemic control was defined with fasting blood glucose level < 130 mg/dL.
|
48 Week
|
Percentage of Participants Achieving Good Glycemic Control (Reduction in HbA1c Values < 6.9 %)
大体时间:48 Week
|
The reported data were percentage of participants who achieved good glycemic control at 48 Week.
Good glycemic control was defined with HbA1c (NGSP) Values < 6.9 %.
|
48 Week
|
Changes From Baseline in Laboratory Parameters (Systolic Blood Pressure (SBP)) at 48 Week
大体时间:From Baseline, Up to 48 Week
|
Changes from baseline in laboratory parameter at 48 Week were reported.
The reported data on this outcome measure is SBP as a one of laboratory parameters.
|
From Baseline, Up to 48 Week
|
Changes From Baseline in Laboratory Parameters (Diastolic Blood Pressure (DBP)) at 48 Week
大体时间:From Baseline, Up to 48 Week
|
Changes from baseline in laboratory parameter at 48 Week were reported.
The reported data on this outcome measure is DBP as a one of laboratory parameters.
|
From Baseline, Up to 48 Week
|
Changes From Baseline in Laboratory Parameters (High-Density Lipoprotein Cholesterol (HDL-Cholesterol)) at 48 Week
大体时间:From Baseline, Up to 48 Week
|
Changes from baseline in laboratory parameter at 48 Week were reported.
The reported data on this outcome measure is HDL-Cholesterol as a one of laboratory parameters.
|
From Baseline, Up to 48 Week
|
Changes From Baseline in Laboratory Parameters (Low-Density Lipoprotein Cholesterol (LDL-Cholesterol)) at 48 Week
大体时间:From Baseline, Up to 48 Week
|
Changes from baseline in laboratory parameter at 48 Week were reported.
The reported data on this outcome measure is LDL-Cholesterol as a one of laboratory parameters.
|
From Baseline, Up to 48 Week
|
Changes From Baseline in Glycosylated Hemoglobin (HbA1c) at 48 Week in Participants Stratified by Dose of Pioglitazone
大体时间:From Baseline, Up to 48 Week
|
The reported data were changes from baseline in laboratory parameter, that is HbA1c (National Glycohemoglobin Standardization Program Criteria; NGSP), at 48 Week in participants stratified by specific characteristics, mean daily dose of pioglitazone, at the time of enrollment.
Mean daily dose of pioglitazone at the time of enrollment were categorized into <15 mg, 15 to <30 mg, 30 <45 mg and 45 mg ≤ as planned (Note; final categorized number of participants was 0 in 45 mg ≤ group).
|
From Baseline, Up to 48 Week
|
Changes From Baseline in HbA1c at 48 Week in Participants Stratified by Levels of HbA1c
大体时间:From Baseline, Up to 48 Week
|
The reported data were changes from baseline in laboratory parameter, that is HbA1c (NGSP), at 48 Week in participants stratified by specific characteristics, Levels of HbA1c, at the time of enrollment.
Levels of HbA1c at the time of enrollment were categorized into <6.2%,
6.2 to <6.9%, 6.9 <7.4%, 7.4 <8.4%, and 8.4% ≤ as planned (Note; final categorized number of participants was 0 in <6.2% and 6.2 to <6.9% group).
|
From Baseline, Up to 48 Week
|
Changes From Baseline in HbA1c at 48 Week in Participants Stratified by Gender
大体时间:From Baseline, Up to 48 Week
|
The reported data were changes from baseline in laboratory parameter, that is HbA1c (NGSP), at 48 Week in participants stratified by specific characteristics, Gender, at the time of enrollment.
Gender was categorized into male and female.
|
From Baseline, Up to 48 Week
|
Changes From Baseline in HbA1c at 48 Week in Participants Stratified by Levels of BMI
大体时间:From Baseline, Up to 48 Week
|
The reported data were changes from baseline in laboratory parameter, that is HbA1c (NGSP), at 48 Week in participants stratified by specific characteristics, Levels of BMI, at the time of enrollment.
Levels of BMI at the time of enrollment were categorized into <18.5 kg/m^2, 18.5 to <25 kg/m^2, 25 <30 kg/m^2, and 30 kg/m^2 ≤.
|
From Baseline, Up to 48 Week
|
Changes From Baseline in HbA1c at 48 Week in Participants Stratified by Presence of Companion Anti-Diabetes Drugs
大体时间:From Baseline, Up to 48 Week
|
The reported data were changes from baseline in laboratory parameter, that is HbA1c (NGSP), at 48 Week in participants stratified by specific characteristics, presence of companion anti-diabetes drugs, at the time of enrollment.
Presence of companion anti-diabetes drugs at the time of enrollment were categorized into Had presence of companion anti-diabetes drugs and Had no presence of companion anti-diabetes drugs.
|
From Baseline, Up to 48 Week
|
Blood Glucose-Related Laboratory Parameters (Fasting Blood Glucose Level) at Each Time Point
大体时间:Baseline and 48 Week
|
Fasting blood glucose level at baseline and 48 Week were reported as one of blood glucose-related laboratory parameters.
|
Baseline and 48 Week
|
Blood Glucose-Related Laboratory Parameters (HbA1c Values) at Each Time Point
大体时间:Baseline and 48 Week
|
HbA1c (NGSP) values at baseline and 48 Week were reported as one of blood glucose-related laboratory parameters.
|
Baseline and 48 Week
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs)
大体时间:Up to 48 Weeks
|
ADRs are defined as adverse events (AEs) which are in the investigator's opinion of causal relationship to the study treatment.
AEs are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug.
|
Up to 48 Weeks
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.